Mubadala Bio has taken a major step forward in the UAE’s healthcare sector by opening a state-of-the-art high-potency pharmaceutical manufacturing facility at its subsidiary, Bioventure Healthcare. Alongside this milestone, the company has launched three essential oncology medicines, some of which are being locally produced for the first time as branded generics.
This achievement strengthens the nation’s pharmaceutical manufacturing landscape and ensures a reliable, continuous supply of critical cancer treatments for patients across the UAE. By introducing these medications to the local market, Mubadala Bio aims to enhance drug security, improve access to essential therapies, and provide more cost-effective treatment options for patients.
Cutting-Edge Facility for High-Potency Medications
The newly opened facility is designed specifically for the production of high-potency drugs, including oncology and hormone therapies. It meets the highest international standards for safety, quality, and regulatory compliance.
Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, emphasized the significance of the launch. He said that this expansion strengthens the life sciences industry in the UAE and delivers tangible benefits to healthcare providers and patients.
“The milestone supports the development of a stronger and more advanced life sciences industry in the country while delivering meaningful benefits through improved access to critical treatments,” said Dr. Al Katheeri.
Key Oncology Drugs Launched
The first medications produced at the facility include:
Lenalidomide – A therapy for treating myeloma, a form of blood cancer.
Pomalidomide – Now locally produced in the UAE for the first time, this drug is used to treat multiple myeloma.
Sunitinib – A targeted therapy for certain advanced or progressive cancers.
These medicines are vital in providing patients with innovative treatments that were previously harder to access locally. The launch of these drugs aligns with Mubadala Bio’s goal of improving the availability of high-quality, cost-effective therapies.
Commitment to National Healthcare and Drug Security
Dr. Essam Mohamed, CEO of Mubadala Bio, highlighted the company’s dedication to strengthening the UAE’s life sciences ecosystem. He noted that by investing in local manufacturing capabilities and launching essential oncology medications, Mubadala Bio is expanding access to crucial medical therapies while ensuring a consistent local supply.
Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, added that the facility reflects the company’s focus on quality and reliability. “The high-potency facility and the launch of three new oncology medicines expand our pharmaceutical capabilities and reinforce our commitment to providing high-quality medical products,” he said.
The development ensures that patients in the UAE have timely access to life-saving medications, reducing dependency on imports and improving national healthcare resilience.
Supporting Long-Term Healthcare Goals
The facility and product launches are part of Mubadala Bio’s broader strategy to support the UAE’s national healthcare priorities. By enhancing local pharmaceutical production, the company is ensuring the long-term availability of essential medicines and contributing to the sustainability of the healthcare system.
This initiative not only benefits patients but also positions the UAE as a growing hub for pharmaceutical innovation. Local production of high-potency oncology drugs is expected to reduce costs, improve patient outcomes, and strengthen the country’s global standing in healthcare manufacturing.
Conclusion
Mubadala Bio’s high-potency facility and the launch of three essential oncology medicines mark a significant milestone for the UAE’s healthcare sector. With a focus on innovation, quality, and accessibility, the company is driving forward the local pharmaceutical industry while ensuring that patients have access to life-saving treatments.
Through these efforts, Mubadala Bio continues to demonstrate its commitment to improving national drug security, enhancing healthcare services, and supporting the UAE’s vision for a robust and sustainable life sciences ecosystem.
Do follow UAE Stories on Instagram
Read Next – teamLab Phenomena Expands with Two New Immersive Artworks
